Live Webinar

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Hosted by AJMC and Targeted Oncology

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Articles|October 1, 2002

Supplements and Featured Publications

  • Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience
  • Volume 8
  • Issue 15 Suppl

Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

Download PDF: Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

Articles in this issue

almost 24 years ago

Participating Faculty

almost 24 years ago

Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience

almost 24 years ago

Prevalence of Cardiovascular Disease Risk Factors Among US Adults With Self-Reported Osteoarthritis: Data from the Third National Health and Nutrition Examination Survey

almost 24 years ago

Comparison of the Baseline Cardiovascular Risk Profile Among Hypertensive Patients Prescribed COX-2-Specific Inhibitors or Nonspecific NSAIDs: Data From Real-Life Practice

almost 24 years ago

Blood Pressure Destabilization and Related Healthcare Utilization Among Hypertensive Patients Using Nonspecific NSAIDs and COX-2-Specific Inhibitors

almost 24 years ago

Cost of Heart Failure Among Hypertensive Users of Nonspecific NSAIDs and COX-2-Specific Inhibitors

almost 24 years ago

Differences Between COX-2-Specific Inhibitors: Clinical and Economic Implications

Related Content